Showing results (31-40 of 159) with videos related to
Sort By:
Pageof 16
Hematology/Oncology Clinics of North America|July 5, 2017
Mechanisms of Resistance to FLT3 Inhibitors and the Role of the Bone Marrow MicroenvironmentGabriel Ghiaur, Mark LevisLeukemia & Lymphoma|May 3, 2008
Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimensKeith Pratz, Mark LevisCurrent Hematologic Malignancy Reports|March 7, 2014
Is targeted therapy feasible in acute myelogenous leukemia?Heiko Konig, Mark LevisHaematologica|July 25, 2020
Potential targeting of FLT3 acute myeloid leukemiaAlexander J Ambinder, Mark LevisF1000Prime Reports|November 7, 2014
Advances in treating acute myeloid leukemiaMargaret M Showel, Mark LevisBlood Advances|March 26, 2020
Gilteritinib: potent targeting of FLT3 mutations in AMLMark Levis, Alexander E PerlExpert Review of Hematology|November 19, 2010
Lestaurtinib: a multi-targeted FLT3 inhibitorAmir T Fathi, Mark LevisBiology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 25, 2019
A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic TransplantationKeith W Pratz, Michelle A Rudek, B Douglas Smith, et al.British Journal of Haematology|October 15, 2013
Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinaseXiaochuan Yang, Amy Sexauer, Mark LevisInvestigational New Drugs|November 18, 2011
Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patientsMaria Cristina Villarroel, Keith W Pratz, Linping Xu, et al.Pageof 16